Christopher E. Kinum, principal, and F. John Fatigati, senior vice president of the Chatham, NJ-based Garibaldi Group, represented Sankyo with the original transaction, the renewal and the expansion. Michael Nevins was the in-house representative for the property's owner, Mack-Cali Realty of Cranford, NJ. "This transaction is another indicator of New Jersey's role in the pharmaceutical industry," according to Fsatigati.
Sankyo develops new classes of medicines for a variety of diseases, including cancer, cardiovascular disease and metabolic disorders. Perhaps its best known brand is the cholesterol-lowering drug, WelChol.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
